The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Open accessPublished version of a preprint
Abstract
Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRASG12C-mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 patients with non–small cell lung cancer (NSCLC), we identified and validated coalterations in KEAP1, SMARCA4, and CDKN2A as major independent determinants of inferior clinical outcomes with KRASG12Ci monotherapy. Collectively, comutations in these three tumor suppressor genes segregated patients into distinct prognostic subgroups and captured ∼50% of those with early disease progression (progression-free survival ≤3 months) with KRASG12Ci. Pathway-level integration of less prevalent coalterations in functionally related genes nominated PI3K/AKT/MTOR pathway and additional baseline RAS gene alterations, including amplifications, as candidate drivers of inferior outcomes with KRASG12Ci, and revealed a possible association between defective DNA damage response/repair and improved KRASG12Ci efficacy. Our findings propose a framework for patient stratification and clinical outcome prediction in KRASG12C-mutant NSCLC that can inform rational selection and appropriate tailoring of emerging combination therapies. Significance: In this work, we identify co-occurring genomic alterations in KEAP1, SMARCA4, and CDKN2A as independent determinants of poor clinical outcomes with KRASG12Ci monotherapy in advanced NSCLC, and we propose a framework for patient stratification and treatment personalization based on the comutational status of individual tumors. See related commentary by Heng et al., p. 1513. This article is highlighted in the In This Issue feature, p. 1501
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Co-mutational analysis revealed that genetic alterations in the PI3K/AKT/mTOR pathway may lead to poorer outcomes of advanced NSCLC patients treated with KRAS G12C inhibitors [109].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“CDKN2A co-mutations are associated with a poor response in advanced NSCLC to KRAS G12C inhibitors [109].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“KEAP1 was also found to be frequently mutated and associated with shorter patient survival in advanced NSCLC resistant to KRAS G12C inhibition [109, 153].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [109]
In the citing paper
“Clinical studies have also shown that KRAS-mutant tumors with certain co-mutations, such as KEAP1 or STK11, are less responsive to certain therapeutic approaches, including anti-PD1 (ref. 58) or KRASG12Ci (ref. 59).”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SIFT: predicting amino acid changes that affect protein function
Ng, P. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg509 · Cited by 6,577
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Self-citationRAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Self-citationHallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Self-citation
Cited by
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Self-citationConcurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Holderfield, M., Lee, B. J., Jiang, J., Tomlinson, A., Seamon, K. J., Mira, A., Patrucco, E., Goodhart, G., Dilly, J., Gindin, Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07205-6 · Cited by 369
“Tissue-specific phenotypes and co-mutation status may also influence RAS dependency 22,23 .”
BackgroundTranslational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0027 · Cited by 343
“Using whole-transcriptome and whole-exome sequencing, we also examined alterations in key genes implicated in NSCLC, PDAC, and colorectal cancer disease etiology (30–32).”
Singhal, A., Li, B. T., & O’Reilly, E. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02903-0 · Cited by 332
“In NSCLC, emerging data suggest that co-occurring genetic mutations in KEAP1 , SMARCA4 and CDKN2A are associated with inferior clinical outcomes to sotorasib therapy 54 , with KEAP1 mutations being associated with a lower response rate across datasets 19,53,55 .”
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
Metadata
- Authors
- Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., Hines, J., Aredo, J. V., Dennis, M. J., Chakrabarti, T., Scott, S. C., Bironzo, P., Scheffler, M., Christopoulos, P., Stenzinger, A., Riess, J. W., Kim, S. Y., Goldberg, S. B., Li, M., Wang, Q., Qing, Y., Ni, Y., Do, M. T., Lee, R., Ricciuti, B., Alessi, J. V., Wang, J., Resuli, B., Landi, L., Tseng, S.-C., Nishino, M., Digumarthy, S. R., Rinsurongkawong, W., Rinsurongkawong, V., Vaporciyan, A. A., Blumenschein, G. R., Zhang, J., Owen, D. H., Blakely, C. M., Mountzios, G., Shu, C. A., Bestvina, C. M., Garassino, M. C., Marrone, K. A., Gray, J. E., Patel, S. P., Cummings, A. L., Wakelee, H. A., Wolf, J., Scagliotti, G. V., Cappuzzo, F., Barlesi, F., Patil, P. D., Drusbosky, L., Gibbons, D. L., Meric-Bernstam, F., Lee, J. J., Heymach, J. V., Hong, D. S., Heist, R. S., Awad, M. M., & Skoulidis, F.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- 1Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- Cleveland Clinic (US)
- Moffitt Cancer Center (US)
- Université Paris-Saclay (FR)
- Instituto Nazionale Tumori Regina Elena (IT)
- University of Chicago Medical Center (US)
- Stanford University (US)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Johns Hopkins University (US)
- University of Turin (IT)
- University Hospital Cologne (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- UC Davis Comprehensive Cancer Center (US)
- Yale University (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Brigham and Women's Hospital (US)
- Henry Dunant Hospital (GR)
- Columbia University (US)
- University of California, Los Angeles (US)
- 6Institut Gustave Roussy, Villejuif, France.
- Guardant (United States) (US)
- 32Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Corresponding author
- Skoulidis, Ferdinandos
- ORCID
- Negrao, Marcelo V.
- Araujo, Haniel A.
- Lamberti, Giuseppe
- Cooper, Alissa J.
- Akhave, Neal S.
- Zhou, Teng
- Delasos, Lukas
- Hicks, J. Kevin
- Aldea, Mihaela
- Minuti, Gabriele
- Hines, Jacobi
- Aredo, Jacqueline V.
- Dennis, Michael J.
- Chakrabarti, Turja
- Scott, Susan C.
- Bironzo, Paolo
- Scheffler, Matthias
- Christopoulos, Petros
- Stenzinger, Albrecht
- Riess, Jonathan W.
- Kim, So Yeon
- Goldberg, Sarah B.
- Li, Mingjia
- Wang, Qi
- Qing, Yun
- Ni, Ying
- Do, Minh Truong
- Lee, Richard
- Ricciuti, Biagio
- Alessi, Joao Victor
- Wang, Jing
- Resuli, Blerina
- Landi, Lorenza
- Tseng, Shu-Chi
- Nishino, Mizuki
- Digumarthy, Subba R.
- Rinsurongkawong, Waree
- Rinsurongkawong, Vadeerat
- Vaporciyan, Ara A.
- Blumenschein, George R.
- Zhang, Jianjun
- Owen, Dwight H.
- Blakely, Collin M.
- Mountzios, Giannis
- Shu, Catherine A.
- Bestvina, Christine M.
- Garassino, Marina Chiara
- Marrone, Kristen A.
- Gray, Jhanelle E.
- Patel, Sandip Pravin
- Cummings, Amy L.
- Wakelee, Heather A.
- Wolf, Juergen
- Scagliotti, Giorgio Vittorio
- Cappuzzo, Federico
- Barlesi, Fabrice
- Patil, Pradnya D.
- Drusbosky, Leylah
- Gibbons, Don L.
- Meric-Bernstam, Funda
- Lee, J. Jack
- Heymach, John V.
- Hong, David S.
- Heist, Rebecca S.
- Awad, Mark M.
- Skoulidis, Ferdinandos
- Venue
- Cancer Discovery
- Published
- 2023-04-17
- Volume
- 13
- Issue
- 7
- Pages
- 1556-1571
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC11024958
- OpenAlex
- W4366198986
- Cited by
- 203
- References
- 44
- Citations by year
- 2026: 48 · 2025: 68 · 2024: 63 · 2023: 24
- FWCI
- 37.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Cancer Institute (NIH/NCI 1R01 CA262469-01)
- NIH Clinical Center (T32-GM07019)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- KRAS G12C, KRAS inhibitors, non-small cell lung cancer, Keap1, SMARCA4, CDKN2A, PI3K/AKT/mTOR pathway, DNA damage response, prognostic factors, patient stratification, personalized treatment, clinicogenomics
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Carcinoma, Non-Small-Cell Lung, DNA Helicases, Humans, Lung Neoplasms, Mutation, Nuclear Proteins, Transcription Factors, Phosphatidylinositol 3-Kinases, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. https://app.cochat.ai/papers/10.1158/2159-8290.cd-22-1420
- The paper
- Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., Hines, J., Aredo, J. V., Dennis, M. J., Chakrabarti, T., Scott, S. C., Bironzo, P., Scheffler, M., Christopoulos, P., Stenzinger, A., . . . Skoulidis, F. (2023). Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-22-1420
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.